Industries Market Research Reports

The CGT landscape has evolved extensively over the past decade. More than 80 CGT products have been commercialized globally, with 34 FDA-approved cell and gene therapies in 2023 alone. The rise in product pipelines and clinical success rates has led to the growing demand for the development of new technology platforms, manufacturing capabilities, a...

The preference for diabetes self-assessment using wearable CGMs instead of finger-stick blood sugar testing is increasing, especially in type 1 diabetics (T1D). HbA1c and time-in-range are currently the preferred biomarkers for diabetes monitoring applications. Emerging diet and fitness tracking apps help support general well-being and prevent the ...